Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
NeuroPro Therapeutics, Inc.
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06525649CT.gov A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042 | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Photosensitive Epilepsy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Npt 2042 (this asset) | NeuroPro Therapeutics, Inc. | P1 | CC · 47 |
| Benzeneethanamine, N-Ethyl-?-Methyl-4-(Trifluoromethyl)-, Hydrochloride, (±)- | Elizabeth Anne Thiele | P3 | BB |
| Valproic Acid | Vanderbilt University Medical Center | P4 | B |
| Act-709478 For Use | Idorsia Pharmaceuticals Ltd. | P2 | B |
| Neurotop | The Epilepsy Study Consortium | P2 | B |
| pf-06372865 | Pfizer | P2 | B |
| Selurampanel | Novartis Pharmaceuticals | P2 | B |
| Lorazepam | Pfizer | P2 | CCC |
| Sulfamide, N-(((2S)-6-Chloro-2,3-Dihydro-1,4-Benzodioxin-2-Yl)Methyl)- | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P2 | CCC |
+2 more in the Photosensitive Epilepsy cohort
Other indications for Npt 2042
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Generalized Epilepsy | — | P2 | CCC · 53 |
| Childhood Absence Epilepsy | — | P2 | CCC · 53 |
| Epilepsy | — | P1 | CCC · 50 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Npt 2042 in Photosensitive Epilepsy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/npt-2042-photosensitive-epilepsy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →